Management of Nephrotic Syndrome with Hypertension

Introduction to Treatment

The American College of Cardiology recommends starting an ACE inhibitor or ARB immediately and uptitrating to the maximum tolerated dose as first-line therapy, targeting systolic blood pressure <120 mmHg, while restricting dietary sodium to <2.0 g/day 1, 2, 3

The American Heart Association suggests targeting systolic blood pressure <120 mmHg using standardized office BP measurement in most adult patients with nephrotic syndrome and hypertension 2, 4, 5
The European Society of Cardiology recommends achieving SBP of 120-130 mmHg as a realistic goal in most patients with glomerular disease 2, 4
For children, the American Academy of Pediatrics recommends targeting 24-hour mean arterial pressure at the 50th percentile for age, sex, and height by ambulatory blood pressure monitoring 2, 5

The National Kidney Foundation advises using ACE inhibitor or ARB as mandatory first-line therapy, uptitrating to the maximally tolerated or FDA-approved daily dose 1, 2, 6, 7
The American College of Cardiology recommends that this dual benefit addresses both hypertension control and proteinuria reduction simultaneously 1, 8, 9

The American Heart Association suggests restricting dietary sodium to <2.0 g/day as this is synergistic with ACE inhibitor/ARB therapy and significantly enhances antiproteinuric effects 1, 2, 4, 11
The Academy of Nutrition and Dietetics recommends normalizing weight through caloric restriction and exercise 1, 4, 11

The European Society of Cardiology recommends using loop diuretics (furosemide) for edema management in nephrotic syndrome, which can be administered as bolus or continuous infusion 8, 6, 10

The National Kidney Foundation advises using potassium-wasting diuretics and/or potassium-binding agents to reduce serum potassium to normal levels, allowing continued use of RAS blocking medications for blood pressure control and proteinuria reduction 1, 2, 4, 11

The American College of Cardiology recommends considering adding mineralocorticoid receptor antagonists (spironolactone or eplerenone) in refractory cases when proteinuria persists despite maximally tolerated ACE inhibitor/ARB therapy and optimal blood pressure control 1, 2, 11

The American Heart Association suggests monitoring labs frequently when on ACE inhibitor or ARB therapy, including serum creatinine, eGFR, potassium levels, and proteinuria 1, 2, 4, 11

The American College of Cardiology recommends considering statin therapy for persistent hyperlipidemia, particularly in patients with other cardiovascular risk factors including hypertension and diabetes 1, 2, 4, 11
The National Lipid Association advises assessing atherosclerotic cardiovascular disease (ASCVD) risk based on LDL-C, apolipoprotein B, triglyceride, and lipoprotein(a) levels 1, 2, 4, 11

The American Heart Association recommends counseling patients to hold ACE inhibitor/ARB and diuretics when at risk for volume depletion, such as during intercurrent illnesses or "sick days" 1, 2, 4, 11